Catalent Clinical Supply Solutions for a Post-Brexit Europe
Minimize Risks to Continuity of Supply in European and UK Studies Posed by the New Brexit Deal
Following the UK vote to leave the EU in 2016, Catalent has worked diligently, alongside our customers, to ensure that we were prepared to maintain continuity of clinical supply to patients across Europe following Brexit, regardless of the outcome.
CATALENT CLINICAL SUPPLY SERVICES OFFERS SPONSORS MITIGATING THE IMPACT OF BREXIT:
- Access to industry-leading experts from our Brexit Strategic Planning Team to best support your risk mitigation activities
- A global network of GMP clinical supply facilities, including sites which have been established and working together in the UK (GB) and EU for 20+ years, to support clinical supply chains across Europe and worldwide
- Brexit solutions that can produce efficiencies in mitigating the risk to clinical supply chain continuity
- A full range of comprehensive clinical supply services, available through our UK (GB) and EU sites